On November 11, 2020, Scott M. Lassman participated in a panel discussion on "Marketing and Launching Complex Generic Drugs Under Regulatory Uncertainty" at the Association for Accessible Medicine's (AAM's) GRx+Biosims 2020 conference. The panel addressed a number of areas of uncertainty, including Q1/Q2 sameness requirements, Product Specific Guidances (PSGs), and exclusivity.
Lassman Law+Policy was recognized by U.S. News & World Report as one of the Best Law Firms in Washington, D.C. in the areas of FDA Law and Administrative/Regulatory Law for 2020. This is the first time the firm has been recognized on this prestigious list.
Scott M. Lassman participated in a panel discussion on October 28, 2020 regarding "FDA-FTC Biologics Promotion Enforcement" at the Food and Drug Law Institute's (FDLI) Advertising and Promotion for Medical Products Conference. Scott's presentation focused on the promotional implications of a recent patent infringement case, GlaxoSmithKline v. Teva, on biosimilars and interchangeable biologics.
Scott M. Lassman gave a presentation on New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on October 15, 2020.
Scott M. Lassman participated in a panel discussion at FDLI's Annual Conference 2020 on October 6, 2020 regarding "Issues and Topics in Litigation Challenging FDA Actions under the Administrative Procedure Act (APA)." Scott's presentation focused on the evolving risks and benefits of challenging FDA actions on Chevron Step Two grounds.
On July 30, 2020, Scott M. Lassman served as the facilitator for a session on "Orphan Drugs: Interesting Cases and New Developments" at FDLI's popular Law Over Lunch series.
Scott M. Lassman will be participating in a panel discussion on June 19, 2020 on Hot Topics in Drug and Medical Device Regulation, which is part of Washington College of Law's Virtual Summer Series on Health Law and Policy (co-sponsored by the American Health Law Association). He will be presenting on new developments regarding orphan drug exclusivity.